EN
SINOVAC Chairman Meets with Chilean President to Foster Bilateral Cooperation
The Company engages in dialogue exploring Chinese investment opportunities in Chile and greater global vaccine accessibility in the interest of human health
October 17, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that SINOVAC’s Chairman, President and CEO, Mr. Weidong Yin, met with Chilean President Gabriel Boric yesterday during his first official visit to China.
As a participant in the "Opportunities in Chile" dialogue hosted by the Chilean Embassy in Beijing on October 16, Mr. Yin joined President Boric and other invited guests to explore opportunities for Chinese entrepreneurs and investment under China’s Belt and Road initiative.
"SINOVAC's mission is to supply vaccines to eliminate human diseases, with a strong commitment to advancing global vaccine accessibility and equity," said Mr. Yin. "Chile is a prime example of our collaborative efforts within the Belt and Road Initiative, where we have made substantial strides in scientific research, clinical trials and local vaccine production. We look forward to President Boric's visit fostering further opportunities for Chinese investments in Chile."
During the exchange, President Boric voiced his support of Chinese investment in Chile, saying he looked forward to continued growth in trade and cooperation between the two countries.
Shared Commitment to Protection Against Human Disease
Mr. Yin's productive talks with President Boric offer an extension of SINOVAC's current work with the Chilean government and organizations on research related to the management and control of infectious diseases, including studies on influenza and Zika.
SINOVAC is investing in local vaccine production capabilities and research facilities in Chile in response to the need to increase regional capacity for infectious disease prevention and control, as well as stronger pre-pandemic preparedness. The Company's market presence includes strong ties with the local ecosystem and a track record of collaboration with Chile's government and healthcare system. Support from the local industry and partners has laid the groundwork for the Company's investments that include the construction of a SINOVAC vaccine production facility in Chile.
History of Long-Standing Partnership
The partnership between SINOVAC and Chilean government began in 2020, as the COVID-19 pandemic was emerging. The pandemic prompted SINOVAC and Chilean scientific experts to explore joint research leveraging Chile's clinical research and data analysis capabilities, as well as the nation's robust healthcare monitoring system.
On July 7, 2021, the results of a real-world study on Chile's mass vaccination with CoronaVac® were published online in the New England Journal of Medicine. These findings facilitated the widespread use of the vaccine in Chile, paved the way for its adoption in other Latin American countries and significantly contributed to the World Health Organization's positive evaluation of the vaccine.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.